146 related articles for article (PubMed ID: 30156074)
1. [Prostate Cancer Prevention Trial risk calculator for evaluating the risk of prostate cancer in the high-risk Chinese population].
Zhu XD; Zheng A; Wang ZQ; Shao Q
Zhonghua Nan Ke Xue; 2018 Feb; 24(2):142-146. PubMed ID: 30156074
[TBL] [Abstract][Full Text] [Related]
2. Development and external multicenter validation of Chinese Prostate Cancer Consortium prostate cancer risk calculator for initial prostate biopsy.
Chen R; Xie L; Xue W; Ye Z; Ma L; Gao X; Ren S; Wang F; Zhao L; Xu C; Sun Y;
Urol Oncol; 2016 Sep; 34(9):416.e1-7. PubMed ID: 27185342
[TBL] [Abstract][Full Text] [Related]
3. Predicting the outcome of prostate biopsy: comparison of a novel logistic regression-based model, the prostate cancer risk calculator, and prostate-specific antigen level alone.
Hernandez DJ; Han M; Humphreys EB; Mangold LA; Taneja SS; Childs SJ; Bartsch G; Partin AW
BJU Int; 2009 Mar; 103(5):609-14. PubMed ID: 19007374
[TBL] [Abstract][Full Text] [Related]
4. The Huashan risk calculators performed better in prediction of prostate cancer in Chinese population: a training study followed by a validation study.
Wu YS; Zhang N; Liu SH; Xu JF; Tong SJ; Cai YH; Zhang LM; Bai PD; Hu MB; Jiang HW; Na R; Ding Q; Sun YH
Asian J Androl; 2016; 18(6):925-929. PubMed ID: 27212127
[TBL] [Abstract][Full Text] [Related]
5. Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment.
Tomlins SA; Day JR; Lonigro RJ; Hovelson DH; Siddiqui J; Kunju LP; Dunn RL; Meyer S; Hodge P; Groskopf J; Wei JT; Chinnaiyan AM
Eur Urol; 2016 Jul; 70(1):45-53. PubMed ID: 25985884
[TBL] [Abstract][Full Text] [Related]
6. The added value of percentage of free to total prostate-specific antigen, PCA3, and a kallikrein panel to the ERSPC risk calculator for prostate cancer in prescreened men.
Vedder MM; de Bekker-Grob EW; Lilja HG; Vickers AJ; van Leenders GJ; Steyerberg EW; Roobol MJ
Eur Urol; 2014 Dec; 66(6):1109-15. PubMed ID: 25168616
[TBL] [Abstract][Full Text] [Related]
7. Do prostate cancer risk models improve the predictive accuracy of PSA screening? A meta-analysis.
Louie KS; Seigneurin A; Cathcart P; Sasieni P
Ann Oncol; 2015 May; 26(5):848-864. PubMed ID: 25403590
[TBL] [Abstract][Full Text] [Related]
8. A comparative effectiveness analysis of the PBCG vs. PCPT risks calculators in a multi-ethnic cohort.
Carbunaru S; Nettey OS; Gogana P; Helenowski IB; Jovanovic B; Ruden M; Hollowell CMP; Sharifi R; Kittles RA; Schaeffer E; Gann P; Murphy AB
BMC Urol; 2019 Nov; 19(1):121. PubMed ID: 31771578
[TBL] [Abstract][Full Text] [Related]
9. Prediction of prostate cancer risk: the role of prostate volume and digital rectal examination in the ERSPC risk calculators.
Roobol MJ; van Vugt HA; Loeb S; Zhu X; Bul M; Bangma CH; van Leenders AG; Steyerberg EW; Schröder FH
Eur Urol; 2012 Mar; 61(3):577-83. PubMed ID: 22104592
[TBL] [Abstract][Full Text] [Related]
10. Observational study comparing the accuracy/variability between the ERSPC and the PCPT risk calculators for the prediction of significant prostate cancer in patients with PSA <10 ng/mL.
Gomez Gomez E; Salamanca Bustos JJ; Carrasco Valiente J; Fernandez Rueda JL; Blanca A; Valero Rosa J; Bravo Arrebola I; Marquez López J; Jimenez Vacas JM; Luque R; Requena Tapia MJ
BMJ Open; 2019 Nov; 9(11):e031032. PubMed ID: 31722940
[TBL] [Abstract][Full Text] [Related]
11. Utility of the transition zone index for identification of prostate cancer in Chinese men with intermediate PSA levels.
Qi TY; Chen YQ; Jiang J; Zhu YK; Yao XH; Wang XJ
Int Urol Nephrol; 2012 Jun; 44(3):807-15. PubMed ID: 22311386
[TBL] [Abstract][Full Text] [Related]
12. Comparison of risk calculators from the Prostate Cancer Prevention Trial and the European Randomized Study of Screening for Prostate Cancer in a contemporary Canadian cohort.
Trottier G; Roobol MJ; Lawrentschuk N; Boström PJ; Fernandes KA; Finelli A; Chadwick K; Evans A; van der Kwast TH; Toi A; Zlotta AR; Fleshner NE
BJU Int; 2011 Oct; 108(8 Pt 2):E237-44. PubMed ID: 21507190
[TBL] [Abstract][Full Text] [Related]
13. Percent free prostate-specific antigen is effective to predict prostate biopsy outcome in Chinese men with prostate-specific antigen between 10.1 and 20.0 ng ml(-1).
Chen R; Zhou LQ; Cai XB; Xie LP; Huang YR; He DL; Gao X; Xu CL; Ding Q; Wei Q; Yin CJ; Ren SC; Wang FB; Tian Y; Sun ZQ; Fu Q; Ma LL; Zheng JH; Ye ZQ; Ye DW; Xu DF; Hou JQ; Xu KX; Yuan JL; Gao X; Liu CX; Pan TJ; Sun YH;
Asian J Androl; 2015; 17(6):1017-21. PubMed ID: 25926603
[TBL] [Abstract][Full Text] [Related]
14. European Randomised Study of Screening for Prostate Cancer (ERSPC) risk calculators significantly outperform the Prostate Cancer Prevention Trial (PCPT) 2.0 in the prediction of prostate cancer: a multi-institutional study.
Foley RW; Maweni RM; Gorman L; Murphy K; Lundon DJ; Durkan G; Power R; O'Brien F; O'Malley KJ; Galvin DJ; Brendan Murphy T; William Watson R
BJU Int; 2016 Nov; 118(5):706-713. PubMed ID: 26833820
[TBL] [Abstract][Full Text] [Related]
15. Prostate cancer detection rate at repeat saturation biopsy: PCPT risk calculator versus PCA3 score versus case-finding protocol.
Pepe P; Aragona F
Can J Urol; 2013 Feb; 20(1):6620-4. PubMed ID: 23433132
[TBL] [Abstract][Full Text] [Related]
16. Phi-based risk calculators performed better in the prediction of prostate cancer in the Chinese population.
Wu YS; Fu XJ; Na R; Ye DW; Qi J; Lin XL; Liu F; Gong J; Zhang N; Jiang GL; Jiang HW; Ding Q; Xu J; Sun YH
Asian J Androl; 2019; 21(6):592-597. PubMed ID: 30924451
[TBL] [Abstract][Full Text] [Related]
17. Improving multivariable prostate cancer risk assessment using the Prostate Health Index.
Foley RW; Gorman L; Sharifi N; Murphy K; Moore H; Tuzova AV; Perry AS; Murphy TB; Lundon DJ; Watson RW
BJU Int; 2016 Mar; 117(3):409-17. PubMed ID: 25847734
[TBL] [Abstract][Full Text] [Related]
18. The impact of prostate volume, number of biopsy cores and American Urological Association symptom score on the sensitivity of cancer detection using the Prostate Cancer Prevention Trial risk calculator.
Ankerst DP; Till C; Boeck A; Goodman P; Tangen CM; Feng Z; Partin AW; Chan DW; Sokoll L; Kagan J; Wei JT; Thompson IM
J Urol; 2013 Jul; 190(1):70-6. PubMed ID: 23313212
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the Prostate Cancer Prevention Trial Risk calculator in a high-risk screening population.
Kaplan DJ; Boorjian SA; Ruth K; Egleston BL; Chen DY; Viterbo R; Uzzo RG; Buyyounouski MK; Raysor S; Giri VN
BJU Int; 2010 Feb; 105(3):334-7. PubMed ID: 19709072
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of PSA-age volume score in predicting prostate cancer in Chinese population.
Wu YS; Wu XB; Zhang N; Jiang GL; Yu Y; Tong SJ; Jiang HW; Mao SH; Na R; Ding Q
Asian J Androl; 2018; 20(4):324-329. PubMed ID: 29405172
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
